Sarepta Therapeutics (NASDAQ:SRPT) Given “Neutral” Rating at Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They currently have a $128.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential downside of 20.36% from the company’s previous close.

Several other research analysts also recently commented on SRPT. Citigroup raised their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Mizuho raised their target price on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a “buy” rating in a research report on Friday, May 17th. UBS Group raised their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Finally, Royal Bank of Canada raised their target price on shares of Sarepta Therapeutics from $142.00 to $182.00 and gave the company a “sector perform” rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.65.

Sarepta Therapeutics Trading Up 30.1 %

SRPT stock opened at $160.72 on Friday. The company has a market capitalization of $15.19 billion, a PE ratio of 1,461.09 and a beta of 0.96. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $173.25. The firm’s 50-day moving average is $125.56 and its 200 day moving average is $119.95. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s revenue was up 63.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.44) EPS. On average, research analysts anticipate that Sarepta Therapeutics will post 2.99 EPS for the current year.

Insider Buying and Selling

In related news, insider Dallan Murray sold 3,635 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after purchasing an additional 243,180 shares in the last quarter. Capital International Investors boosted its stake in Sarepta Therapeutics by 1.6% in the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after purchasing an additional 76,032 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after purchasing an additional 319,444 shares in the last quarter. Wellington Management Group LLP lifted its stake in Sarepta Therapeutics by 5.6% during the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after acquiring an additional 217,810 shares during the period. Finally, Farallon Capital Management LLC lifted its stake in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.